Background
extensive-stage small-cell lung cancer, Cancer
CANCER
Edited by: Lian Xiang Luo, Guangdong Medical University, ChinaReviewed by: Jialin Shang, Cornell University, United States; Hua Zhong, University of Hawaii at Manoa, United States; Lingjie Sang, University of Texas Southwestern Medical Center, United States; Yuanyuan Ji, University of Maryland, United States†These authors share last authorshipThis article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in ImmunologyProgrammed cell death-ligand 1 (PD-L1) inhibitors plus chemotherapy have made substantial progress in extensive-stage small-cell lung cancer (ES-SCLC), but the survival benefit is still limited. This study aimed to evaluate the preliminary efficacy and safety of camrelizumab plus platinum-irinotecan (IP/IC) followed by maintenance camrelizumab plus apatinib in patients with untreated ES-SCLC.